Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ

ERJ Open Research

Volumn 3, Issue 3, 2017, Pages

  Wang, Jing ^a,b   Lesko, Melissa ^b   Badri, Michelle H ^c   Kapoor, Bianca C ^b   Wu, Benjamin G ^b   Li, Yonghua ^b   Smaldone, Gerald C ^d   Bonneau, Richard ^c,e,f   Kurtz, Zachary D ^b   Condos, Rany ^b   Segal, Leopoldo N ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f Simons Center for Data Analysis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA2 INTERFERON; CARBON MONOXIDE; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; FIT 3 LIGAND; GAMMA INTERFERON; INTERLEUKIN 5; INTERLEUKIN 8; LYMPHOTOXIN; MEMBRANE PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR AA; RNA 16S; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACTINOMYCETALES; ADULT; AGED; ARTICLE; BIOASSAY; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; ECHOGRAPHY; EX VIVO STUDY; FEMALE; FIBROSING ALVEOLITIS; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; INTERSTITIAL PNEUMONIA; LACHNOSPIRACEAE; LUMINEX ASSAY; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; LUNG MICROBIOME; MALE; MICROBIOME; MIDDLE AGED; NONHUMAN; OPEN LUNG BIOPSY; PHENOTYPE; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SIX MINUTE WALK TEST; TOTAL LUNG CAPACITY;

EID: 85081956412     PISSN: None     EISSN: 23120541     Source Type: Journal    
DOI: 10.1183/23120541.00008-2017     Document Type: Article

References (37)

1. Spagnolo P, Sverzellati N, Rossi G, et al. Idiopathic pulmonary fibrosis: an update. Ann Med 2015; 47: 15-27.
2. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-142.
3. Salvioli B, Belmonte G, Stanghellini V, et al. Gastro-oesophageal reflux and interstitial lung disease. Dig Liver Dis 2006; 38: 879-884.
4. Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1804-1808.
5. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. Am J Respir Crit Care Med 2005; 172: 1605.
6. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586-593.
7. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190: 906-913.
8. Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014; 2: 548-556.
9. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
10. Narayanan AS, Whithey J, Souza A, et al. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992; 101: 1326-1331.
11. Okada T, Sugie I, Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res 1993; 12: 87-91.
12. Clark JG, Dedon TF, Wayner EA, et al. Effects of interferon-gamma on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J Clin Invest 1989; 83: 1505-1511.
13. King TE., Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
14. Dawson R, Condos R, Tse D, et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One 2009; 4: e6984.
15. Diaz KT, Skaria S, Harris K, et al. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv 2012; 25: 79-87.
16. Segal LN, Clemente JC, Tsay JC, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol 2016; 1: 16031.
17. Scher JU, Joshua V, Artacho A, et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome 2016; 4: 60.
18. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12: 60.
19. Ramanan D, Bowcutt R, Lee SC, et al. Helminth infection promotes colonization resistance via type 2 immunity. Science 2016; 352: 608-612.
20. Kolahian S, Fernandez IE, Eickelberg O, et al. Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol 2016; 55: 309-322.
21. Segal LN, Alekseyenko AV, Clemente JC, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 2013; 1: 19.
22. Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol 2014; 12: 87.
23. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241-1257.
24. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.
25. Keane MP, Belperio JA, Burdick MD, et al. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2001; 281: L92-L97.
26. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
27. Le TT, Karmouty-Quintana H, Melicoff E, et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol 2014; 193: 3755-3768.
28. Segal LN, Rom WN, Weiden MD. Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs. Ann Am Thorac Soc 2014; 11: 108-116.
29. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013; 68: 155-162.
30. Molyneaux PL, Willis-Owen SAG, Cox MJ, et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017; 195: 1640-1650.
31. Segal LN, Clemente JC, Wu BG, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax 2017; 72: 13-22.
32. Sgalla G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history. Respirology 2016; 21: 427-437.
33. Dickson RP, Erb-Downward JR, Freeman CM, et al. Bacterial topography of the healthy human lower respiratory tract. mBio 2017; 8: e02287-16.
34. Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio 2015; 6: e00037-15.
35. Dickson RP, Erb-Downward JR, Martinez FJ, et al. The microbiome and the respiratory tract. Annu Rev Physiol 2016; 78: 481-504.
36. Dickson RP, Erb-Downward JR, Prescott HC, et al. Cell-associated bacteria in the human lung microbiome. Microbiome 2014; 2: 28.
37. Segal LN, Dickson RP. The lung microbiome in HIV. Getting to the HAART of the host-microbe interface. Am J Respir Crit Care Med 2016; 194: 136-137.